Back to top

Carisma Therapeutics, OrthoCellix enter definitive merger agreement

Carisma Therapeutics (CARM) and OrthoCellix, a wholly-owned subsidiary of Ocugen (OCGN), announced that they have entered into a definitive merger ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Carisma Therapeutics Inc. (CARM)

Ocugen, Inc. (OCGN)